Article Text

SAT0055 Treatment Response To Conventional Disease Modifying Anti-Rheumatic Drugs (Dmards) and Biologics in Seropositive and Seronegative Patients with Early Rheumatoid Arthritis: Results from Catch (Canadian Early Arthritis Cohort)
  1. B. Aberumand1,
  2. V. Bykerk2,
  3. O. Schieir3,
  4. D. Lin2,
  5. G. Boire4,
  6. B. Haraoui5,
  7. C.A. Hitchon6,
  8. C. Thorne7,
  9. D. Tin7,
  10. E.C. Keystone2,
  11. S. Jamal8,
  12. J.E. Pope9
  1. 1Medicine, Schulich School of Medicine and Dentistry, London
  2. 2Mount Sinai Hospital
  3. 3University of Toronto Dalla Lana School of Public Health, Toronto
  4. 4Medicine, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke
  5. 5Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal
  6. 6Medicine, University of Manitoba, Winnipeg
  7. 7Southlake Regional Health Centre, Newmarket
  8. 8University of British Columbia, Vancouver
  9. 9Schulich School of Medicine and Dentistry, London, Canada


Background Rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) status may affect treatment response in early rheumatoid arthritis (ERA).

Objectives To investigate differences in treatment response to disease modifying anti-rheumatic drugs (DMARDs) and biologics in ERA in seropositive versus seronegative patients for RF and/or ACPA.

Methods Data were obtained from The Canadian Early Arthritis Cohort (CATCH), a prospective multi-site study of patients with ERA who met 1987 or 2010 ACR/EULAR criteria for RA, had symptom duration <1 year, were not in remission at baseline and had RF or ACPA available, DAS28 scores at baseline and follow-up. Stratified multiple linear regression compared the effects of initial treatment with methotrexate (MTX) monotherapy, MTX combination therapy (defined as MTX plus one or more conventional DMARD), biologic therapy and other therapy on change in DAS28 (D DAS) at 3 and 6 month follow up in patients who were seropositive (RF + and/or ACPA+) and seronegative (RF- and ACPA-), patients who were RF positive and RF negative, and patients who were ACPA positive and ACPA negative, respectively. All multivariable models were adjusted for baseline age, gender, education, ethnicity, symptom duration, comorbidities, erosions and pain scores.

Results 1068 patients had a baseline mean (SD) age of 53.3 (15.0), symptom duration of 5.8 (3.0) months, DAS28 of 5.2 (1.3) and 74% were female. A total of 867 (81.2%) patients were seropositive and 201 (18.8%) were seronegative (RF positive 759 [66%], RF negative 385 [34%], ACPA positive 539 [61%], and ACPA negative 349 [39%]). Relative to the other therapy group, better treatment response to methotrexate combination therapy at 3 months was observed for patients who were RF+ (β: 0.45 [95% CI -0.74 to -0.17]) vs. RF- (β: 0.29 [95% CI -0.14 to 0.71]) and the combined seropositive (β: -0.29 [95% CI -0.56 to -0.02]) vs. seronegative group (β: -0.12 [95% CI -0.69 to 0.44) but not patients who were ACPA+ (β: -0.06 [95% CI -0.41 to 0.30]) vs. ACPA- (β: -0.41 [95% CI -0.84 to 0.02]), after adjusting for covariates. Similar results were observed when analyses were repeated with change in DAS at 6-months as the outcome as patients on methotrexate combination therapy who were RF+ (β: -0.47 [95% CI -0.81 to -0.13]) vs. RF- (β 0.15 [95% CI -0.39 to 0.71]) and those that were seropositive (β -0.32 [95% CI -0.65 to 0.00]) vs. seronegative (β: -0.20 [95% CI -0.97 to 0.56]) responded better to treatment. Response to other treatment strategies did not significantly differ by antibody in any grouping (Table).

Conclusions In ERA, RF and ACPA status affected treatment response to MTX combination therapy, with better changes in DAS28 at 3 and 6-months in seropositive compared with seronegative patients. Given the complexity of rheumatoid arthritis management, the study findings potentially have implications for identifying prognostic indicators that may help inform therapeutic decision-making.

Disclosure of Interest None declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.